Pharma
China's clinical trials are known for their speed and cost advantages, but three deaths reported over the summer, including two children, have raised questions about U.S. FDA data review and regulatory transparency.
AstraZeneca and Amgen jointly announced that their immunology drug Tezspire achieved all primary goals in a Phase III study for eosinophilic esophagitis. The drug is already approved for severe asthma and chronic rhinosinusitis, and if the new indication is approved, it will directly compete with Sanofi and Regeneron's Dupixent. Both companies reported Tezspire sales exceeding $1 billion each in 2025, with AstraZeneca's Q2 2026 revenue reaching $390 million, a 45% year-over-year increase.
Our partners
PAI银行新闻网
PAI生物制药新闻网
PAI财务资讯新闻网
PAIIT信息新闻网
PAI银行资讯站
PAI社会新闻网
PAI用户调研新闻网
PAI网络安全新闻网
PAIES综合新闻网
PAI基础设施科技新闻网
PAI食品科技新闻网
PAI生鲜百货新闻网
PAI医疗保健新闻网
PAI高等教育新闻网
PAI酒店新闻网
PAI人力资源新新闻网
PAIK12教育新闻网
PAI制造业新闻网
PAI市场营销新闻网
PAI医疗技术新闻网
PAI住宅新闻网
PAI包装行业新闻网
PAI支付行业新闻网
PAI生物技术新闻网
PAI资本预算新闻网
PAI外卖行业新闻网
PAI智慧零售新闻网
PAI智慧城市新闻网
PAI新媒体营销新闻网
PAI供应链新闻网
PAI运输业新闻网
PAI电力储能新闻网
PAI汽车新闻网